Billie Lo
2021-12-17
๐๐๐๐
Pfizer files for full FDA approval of COVID-19 vaccine in adolescents
ๅ ่ดฃๅฃฐๆ๏ผไธ่ฟฐๅ ๅฎนไป ไปฃ่กจๅๅธไบบไธชไบบ่ง็น๏ผไธๆๆๆฌๅนณๅฐ็ไปปไฝๆ่ตๅปบ่ฎฎใ
ๅไบซ่ณ
ๅพฎไฟก
ๅคๅถ้พๆฅ
็ฒพๅฝฉ่ฏ่ฎบ
ๆไปฌ้่ฆไฝ ็็็ฅ็ผ่งๆฅๅกซ่กฅ่ฟ็็ฉบ็ฝ
ๆๅผAPP๏ผๅ่กจ็ๆณ
APPๅ ๆๅผ
ๅ่กจ็ๆณ
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":699932341,"tweetId":"699932341","gmtCreate":1639733496538,"gmtModify":1639733496538,"author":{"id":3569982147441048,"idStr":"3569982147441048","authorId":3569982147441048,"authorIdStr":"3569982147441048","name":"Billie Lo","avatar":"https://static.tigerbbs.com/2de8913068819a9735f0bb22ec7a5e72","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3907,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>๐๐๐๐</p></body></html>","htmlText":"<html><head></head><body><p>๐๐๐๐</p></body></html>","text":"๐๐๐๐","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699932341","repostId":2192942298,"repostType":2,"repost":{"id":"2192942298","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639727367,"share":"https://www.laohu8.com/m/news/2192942298?lang=&edition=full","pubTime":"2021-12-17 15:49","market":"us","language":"en","title":"Pfizer files for full FDA approval of COVID-19 vaccine in adolescents","url":"https://stock-news.laohu8.com/highlight/detail?id=2192942298","media":"Reuters","summary":"Dec 16 (Reuters) - Pfizer Inc and its German partner BioNTech SE said on Thursday they have filed fo","content":"<p>Dec 16 (Reuters) - Pfizer Inc and its German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> said on Thursday they have filed for full approval of their COVID-19 vaccine with the U.S. Food and Drug Administration to include adolescents aged 12 to 15.</p>\n<p>The vaccine received full approval for ages 16 and above in the United States in August. The shot also has an emergency use authorization for 5 to 15 year olds.</p>\n<p>Pfizer is seeking for an approval based on long-term data from a late-stage study conducted among adolescents. The company said in November the two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose.</p>\n<p>The company is seeking clearance for a 30 micrograms dose of the vaccine for those aged 12 and above. Pfizer/BioNTech's vaccine is the only COVID-19 vaccine authorized for the given age group in the U.S.</p>\n<p>Pfizer said it expects to file for approval with the European Medicines Agency and other regulatory authorities around the world in the coming weeks.</p>\n<p>The FDA gave the two-dose vaccine emergency-use authorization for adolescents in May.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer files for full FDA approval of COVID-19 vaccine in adolescents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer files for full FDA approval of COVID-19 vaccine in adolescents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-17 15:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 16 (Reuters) - Pfizer Inc and its German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> said on Thursday they have filed for full approval of their COVID-19 vaccine with the U.S. Food and Drug Administration to include adolescents aged 12 to 15.</p>\n<p>The vaccine received full approval for ages 16 and above in the United States in August. The shot also has an emergency use authorization for 5 to 15 year olds.</p>\n<p>Pfizer is seeking for an approval based on long-term data from a late-stage study conducted among adolescents. The company said in November the two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose.</p>\n<p>The company is seeking clearance for a 30 micrograms dose of the vaccine for those aged 12 and above. Pfizer/BioNTech's vaccine is the only COVID-19 vaccine authorized for the given age group in the U.S.</p>\n<p>Pfizer said it expects to file for approval with the European Medicines Agency and other regulatory authorities around the world in the coming weeks.</p>\n<p>The FDA gave the two-dose vaccine emergency-use authorization for adolescents in May.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"่พ็","BK4534":"็ๅฃซไฟก่ดทๆไป","BK4568":"็พๅฝๆ็ซๆฆๅฟต","BK4550":"็บขๆ่ตๆฌๆไป","BK4533":"AQR่ตๆฌ็ฎก็(ๅ จ็็ฌฌไบๅคงๅฏนๅฒๅบ้)","BK4007":"ๅถ่ฏ","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192942298","content_text":"Dec 16 (Reuters) - Pfizer Inc and its German partner BioNTech SE said on Thursday they have filed for full approval of their COVID-19 vaccine with the U.S. Food and Drug Administration to include adolescents aged 12 to 15.\nThe vaccine received full approval for ages 16 and above in the United States in August. The shot also has an emergency use authorization for 5 to 15 year olds.\nPfizer is seeking for an approval based on long-term data from a late-stage study conducted among adolescents. The company said in November the two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose.\nThe company is seeking clearance for a 30 micrograms dose of the vaccine for those aged 12 and above. Pfizer/BioNTech's vaccine is the only COVID-19 vaccine authorized for the given age group in the U.S.\nPfizer said it expects to file for approval with the European Medicines Agency and other regulatory authorities around the world in the coming weeks.\nThe FDA gave the two-dose vaccine emergency-use authorization for adolescents in May.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2058,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/699932341"}
็ฒพๅฝฉ่ฏ่ฎบ